Hematological toxicity: experience with anthracyclines and anthracenes.

Area of Science:

• Oncology
• Pharmacology
• Hematology

Background:

• Hemopoietic toxicity is a significant concern in cancer chemotherapy.
• Anthracyclines and anthracenes are commonly used antineoplastic agents.
• Understanding drug-specific toxicity profiles is crucial for optimizing treatment regimens.

Purpose of the Study:

• To document and compare the hemopoietic toxicity of various anthracyclines and anthracenes.
• To assess toxicity in patients with primary liver cancer (PLC), metastatic breast cancer, and colorectal cancer.
• To evaluate the impact of different dosing and combination regimens on toxicity.

Main Methods:

• Retrospective analysis of hemopoietic toxicity data.
• Comparison of toxicity between mitoxantrone and doxorubicin (ADR) in PLC patients.
• Evaluation of esorubicin versus 4-'epidoxorubicin (4-'epiADR) in colon cancer.
• Assessment of cumulative leukopenia and thrombocytopenia.
• Analysis of dose delivery across treatment cycles and disease categories.

Main Results:

• Mitoxantrone (14 mg/m2 TIW) was significantly more toxic than ADR (60 mg/m2 TIW) in PLC patients (P < 0.01).
• Esorubicin and 4-'epiADR showed similar toxicity in colon cancer patients.
• Cumulative leukopenia was observed with mitoxantrone and esorubicin; cumulative thrombocytopenia with mitoxantrone and ADR.
• Dose delivery varied by drug and disease category, despite similar nadir counts in early cycles.
• Combination chemotherapy (e.g., cyclophosphamide + ADR + fluorouracil) showed improved outcomes without excessive toxicity in breast cancer.

Conclusions:

• Different anthracyclines and anthracenes exhibit varying hemopoietic toxicity profiles.
• Drug selection and combination strategies can influence toxicity and treatment outcomes.
• Careful monitoring of hemopoietic parameters is essential during treatment with these agents.